In pursuit of new lupus therapies: The importance of trial endpoints

Author: Claire Barnard The two phase 3 trials of anifrolumab for the treatment of systemic lupus erythematosus (SLE) reported different primary results, with TULIP-1 finding no significant difference in SRI-4 response rates among patients treated with anifrolumab versus placebo, and TULIP-2 demonstrating significantly higher BICLA response rates with the type I interferon receptor-targeted monoclonal antibody. Why did these two trials report apparently contradictory […]

Real-world studies of SGLT2 inhibition and amputation risk

The results of the CANVAS program showed that patients with type 2 diabetes taking canagliflozin had an increased risk for amputation of the toes, feet, or legs, with a rate per 1000 patient–years of 6.3 versus 3.4 in the placebo group. Of note, however, the amputation rate in the CANVAS placebo group was around half of […]

The UKPDS: A lasting legacy

The results of the UK Prospective Diabetes Study (UKPDS) changed the face of diabetes treatment, addressing fundamental questions about the condition, the answers to which still underpin the management of people with diabetes today. And it was a mammoth undertaking, spawning 93 original research papers to date, far exceeding the trialists’ initial expectations for duration […]

At a glance: Common scores used in rheumatology

Author: Claire Barnard A number of different scores, many of them composite outcomes, are used in daily rheumatology practice and in clinical trials to assess the efficacy of new treatments. This article provides a quick-reference guide to the criteria that are commonly used, together with an explanation of the component parts making up the individual […]

At a glance: The KEYNOTE lung cancer trials

doctor with stack of files

Updated July 2019 Author: Shreeya Nanda The PD-1 inhibitor pembrolizumab is being investigated in multiple KEYNOTE trials across different tumor types, either alone or as part of various combinations, leading to a prodigious amount of information. Here we provide a quick guide to the non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) trials sponsored […]

A quick guide to the SUSTAIN trials

(Updated June 2021) There are a confusing number of SUSTAIN phase 3 trials either completed or in process, investigating the once-weekly injectable glucagon-like peptide-1 analog semaglutide in patients with type 2 diabetes. The trials are all sponsored by the drug-maker, Novo Nordisk. Here is our guide to the 15 trials launched to date, which are complete, […]